- ISIN
- US23255M1053
- CUSIP
- 23255M105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 2, 2019
Highlights
- Market Cap
- $13.75M
- Enterprise Value
- $10.93M
- EPS (TTM)
- -$0.61
- Total Revenue (TTM)
- $1.99M
- Gross Profit (TTM)
- $1.99M
- EBITDA (TTM)
- -$6.70M
- Year Range
- $1.03 - $8.48
- ROA (TTM)
- -24.68%
- ROE (TTM)
- -30.91%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CYCN Performance Chart
Cyclerion Therapeutics, Inc. (CYCN) is up 157.5% since the beginning of the year. At $3 per share, CYCN is trading 61.4% below its 52-week high of $8. Investors who bought $1,000 worth of CYCN shares 5 years ago would now be looking at an investment worth $41.
Loading charts...
Returns By Period
Cyclerion Therapeutics, Inc. (CYCN) has returned 157.48% so far this year and 13.54% over the past 12 months.
Cyclerion Therapeutics, Inc.
- 1D
- 1.55%
- 1M
- 2.83%
- YTD
- 157.48%
- 6M
- 128.67%
- 1Y
- 13.54%
- 3Y*
- -9.07%
- 5Y*
- -47.16%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
CYCN Monthly Returns History
Based on dividend-adjusted daily data since Apr 2, 2019, CYCN's average daily return is +0.25%, while the average monthly return is -0.52%.
Historically, 38% of months were positive and 62% were negative. The best month was Apr 2026 with a return of +113.6%, while the worst month was Oct 2019 at -80.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CYCN closed higher 45% of trading days. The best single day was Apr 1, 2026 with a return of +311.6%, while the worst single day was Oct 30, 2019 at -79.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.09% | -0.74% | 14.81% | 113.55% | -4.83% | 3.81% | 157.48% | ||||||
| 2025 | 21.74% | -31.89% | -6.37% | 38.00% | -18.55% | 3.56% | -8.93% | -6.79% | -6.88% | -18.70% | -15.51% | -19.62% | -60.56% |
| 2024 | -10.45% | -0.00% | 6.67% | -11.56% | -5.65% | -13.86% | 55.65% | -18.16% | -11.60% | 11.58% | -23.88% | 46.36% | -3.88% |
| 2023 | 2.21% | -2.94% | -33.35% | -36.39% | -21.19% | -5.29% | -22.42% | 12.32% | -4.74% | -23.98% | -16.15% | 53.67% | -74.47% |
| 2022 | -23.26% | -20.45% | 5.71% | -33.65% | -15.47% | -11.85% | 74.93% | -12.50% | 2.38% | -36.05% | 72.73% | -30.93% | -61.85% |
| 2021 | 3.27% | 21.52% | -27.34% | -21.86% | 48.62% | 20.37% | -25.38% | 17.53% | -10.23% | -16.61% | -14.84% | -21.10% | -43.79% |
Benchmark Metrics
Cyclerion Therapeutics, Inc. has an annualized alpha of 57.83%, beta of 1.18, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since April 02, 2019.
- This stock participated in 174.41% of S&P 500 Index downside but only -53.15% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 57.83%
- Beta
- 1.18
- R²
- 0.01
- Upside Capture
- -53.15%
- Downside Capture
- 174.41%
Return for Risk
Risk / Return Rank
CYCN ranks 64 for risk / return — better than 64% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cyclerion Therapeutics, Inc. (CYCN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CYCN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.74 | ||
| Sortino ratioReturn per unit of downside risk | +0.88 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.32 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.19 | 2.46 | -2.26 |
| Martin ratioReturn relative to average drawdown | 0.28 | 10.92 | -10.64 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cyclerion Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cyclerion Therapeutics, Inc. was 99.72%, occurring on Feb 5, 2026. The portfolio has not yet recovered.
The current Cyclerion Therapeutics, Inc. drawdown is 99.16%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.72%Feb 2026 | 6y 10mo | — | 7y 2moApr 2019 - now |
Drawdown Indicators
| CYCN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.72% | -56.78% | -42.94% |
Max Drawdown (1Y)Largest decline over 1 year | -70.33% | -9.10% | -61.23% |
Max Drawdown (3Y)Largest decline over 3 years | -82.99% | -18.90% | -64.09% |
Max Drawdown (5Y)Largest decline over 5 years | -98.70% | -25.43% | -73.27% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.16% | -3.21% | -95.95% |
Average DrawdownAverage peak-to-trough decline | -88.45% | -10.71% | -77.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.48% | 2.04% | +46.44% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cyclerion Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cyclerion Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CYCN relative to other companies in the Biotechnology industry. Currently, CYCN has a P/S ratio of 5.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CYCN in comparison with other companies in the Biotechnology industry. Currently, CYCN has a P/B value of 2.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CYCN
Add Cyclerion Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CYCN